Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 244

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Postoperative Radiotherapy for Pathologic N2 Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base

Open access
Robinson, Cliff G., Patel, Aalok P., Bradley, Jeffrey D., DeWees, Todd, Waqar, Saiama N., Morgensztern, Daniel, Baggstrom, Maria Q., Govindan, Ramaswamy, Bell, Jennifer M., Guthrie, Tracey J., Colditz, Graham A., Crabtree, Traves D., Kreisel, Daniel, Krupnick, Alexander S., Patterson, G. Alexander, Meyers, Bryan F., Puri, Varun·2015·Journal of Clinical Oncology

Abstract

Purpose: To investigate the impact of modern postoperative radiotherapy (PORT) on overall survival (OS) for patients with N2 non–small-cell lung cancer (NSCLC) treated nationally with surgery and adjuvant chemotherapy. Patients and Methods: Patients with pathologic N2 NSCLC who underwent complete resection and adjuvant chemotherapy from 2006 to 2010 were identified from the National Cancer Data Base and stratified by use of PORT (≥ 45 Gy). A total of 4,483 patients were identified (PORT, n = 1,850; no PORT, n = 2,633). The impact of patient and treatment variables on OS was explored using Cox regression. Results: Median follow-up time was 22 months. On univariable analysis, improved OS correlated with younger age, treatment at an academic facility, female sex, urban population, higher income, lower Charlson comorbidity score, smaller tumor size, multiagent chemotherapy, resection with at least a lobectomy, and PORT. On multivariable analysis, improved OS remained independently predicted by younger age, female sex, urban population, lower Charlson score, smaller tumor size, multiagent chemotherapy, resection with at least a lobectomy, and PORT (hazard ratio, 0.886; 95% CI, 0.798 to 0.988). Use of PORT was associated with an increase in median and 5-year OS compared with no PORT (median OS, 45.2 v 40.7 months, respectively; 5-year OS, 39.3% [95% CI, 35.4% to 43.5%] v 34.8% [95% CI, 31.6% to 38.3%], respectively; P = .014). Conclusion: For patients with N2 NSCLC after complete resection and adjuvant chemotherapy, modern PORT seems to confer an additional OS advantage beyond that achieved with adjuvant chemotherapy alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.58.5380

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 244

Metadata

Authors
Robinson, C. G., Patel, A. P., Bradley, J. D., DeWees, T., Waqar, S. N., Morgensztern, D., Baggstrom, M. Q., Govindan, R., Bell, J. M., Guthrie, T. J., Colditz, G. A., Crabtree, T. D., Kreisel, D., Krupnick, A. S., Patterson, G. A., Meyers, B. F., & Puri, V.
Venue
Journal of Clinical Oncology
Published
2015-03-10
Volume
33
Issue
8
Pages
870-876
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2158499570
Cited by
244
References
4
FWCI
20.22
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Postoperative Radiotherapy for Pathologic N2 Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base. https://app.cochat.ai/papers/10.1200/jco.2014.58.5380
The paper
Robinson, C. G., Patel, A. P., Bradley, J. D., DeWees, T., Waqar, S. N., Morgensztern, D., Baggstrom, M. Q., Govindan, R., Bell, J. M., Guthrie, T. J., Colditz, G. A., Crabtree, T. D., Kreisel, D., Krupnick, A. S., Patterson, G. A., Meyers, B. F., & Puri, V. (2015). Postoperative Radiotherapy for Pathologic N2 Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.58.5380

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.